

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-17. Canceled

18. (Previously presented) A biodegradable depot medicament formulation comprising:

(i) a carrier system comprising a biodegradable blood plasma protein, which has been dried by fluidized bed drying with retention of its properties, wherein said blood plasma protein is selected from the group consisting of thrombin, fibrinogen, albumin, and mixtures thereof, and wherein the carrier system is in the form of microporous granules with a particle size in the range from 20 to 500 μm , and

(ii) an active ingredient, which is to be administered as a depot or as an active ingredient combination.

19. (Previously presented) The depot medicament formulation of claim 18, wherein the carrier system is a solid which has been produced by compression of the granules.

20. (Currently amended) The depot medicament formulation of claim 18, characterized in that it is in the form of a granule mixture of (i) granules of particles of the carrier system and (ii) granules of the active ingredient.

21. (Currently amended) The depot medicament formulation of claim 18, characterized in that it is in the form of mixed granules of containing both the biodegradable blood plasma protein and of the active ingredient or of the active ingredient combination thereof.

22. (Previously presented) The depot medicament formulation of claim 18, characterized in that it is composed of mixtures of particles or granules which are formed of an internal core and an external layer, wherein the external layer has been formed by the blood plasma protein, and the internal core comprises an inert excipient.

23. (Previously presented) The depot medicament formulation of claim 22, wherein the inert excipient is a carbohydrate selected from the group consisting of lactose and mannitol.

24. (Previously presented) The depot medicament formulation of claim 18, characterized in that it is in the form of compact homogeneous micropellets with an average particle diameter in the range from 35 to 500 μm .

25. (Previously presented) The depot medicament formulation of claim 24, wherein the average particle diameter is in the range from 50 to 150 μm .

26. (Previously presented) The depot medicament formulation of claim 18, characterized in that it comprises ceramic granules, or calcium phosphates, or both, which have been compressed together to give a shaped article and which have then been coated with the blood plasma protein.

27. (Previously presented) The depot medicament formulation of claim 26, wherein the blood plasma protein coating further comprises antibiotics, or growth factors, or both.

28. (Previously presented) The depot medicament formulation of claim 18 or 27, wherein the active ingredient is selected from the group consisting of antibiotics, corticosteroids, antimycotics, neuroleptics, antiepileptics, steroid hormones, anticancer hormones, substances which promote wound healing, cytostatics, immunomodulators, anesthetics, analgesics, peptide hormones, antirheumatics, vaccines, antibodies, nucleic acids, peptides, proteins, growth factors, cells, and combinations thereof.

29. (Previously presented) The depot medicament formulation of claim 18, characterized in that it is employed for topical administration.

30. (Previously presented) The depot medicament formulation of claim 18, characterized in that it is employed for parenteral administration.

31. (Previously presented) The depot medicament formulation of claim 18, characterized in that it is employed for transdermal administration.

32. (Previously presented) The depot medicament formulation of claim 26 or 27, characterized in that it is employed as an implant.

33. (Previously presented) The depot medicament formulation of claim 32, wherein the implant is a bone replacement.

34. (Previously presented) A process for producing the depot medicament formulation of claim 18 comprising:

(i) spraying the biodegradable blood plasma protein in the form of a solution, or suspension, or both into a fluidized bed installation, and

(ii) drying under mild conditions with retention of the properties.